A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Terminated · Phase 2 · NCT06028230
Conditions: Hidradenitis Suppurativa
At a glance
- Research payments reported, 2025
- $1.1M
- U.S. investigators named
- 18
- Sites paid
- 20
- Planned or actual enrollment
- 70
About the trial
- Sponsor
- Sanofi (with Kymera Therapeutics, Inc.)
- Tested
- SAR444656 (KT-474) (drug), Placebo (drug)
- Dates
- Started 2023-09-29; completion 2025-11-12
- Results posted
- Not yet
This is a parallel, Phase 2, 3-arm study to evaluate the efficacy, safety, PK, and biological effects of SAR444656 compared with placebo in adult participants with moderate to severe HS aged ≥18 to 70 years. Study details include: * Screening period: up to 4 weeks (30 days) * Treatment duration: up to 16 weeks * Follow-up period: up to 4 weeks * Total study duration: up to 24 weeks * Number of visits: 14
From ClinicalTrials.gov, last updated 2025-12-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $1.1M in research payments for this study in 2025 (290 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Christopher V. Crosby, M.D., PH.D. Mohs Surgery · La Mesa, CA
- Cheryl L. Effron, M.D. Specialist · Anaheim, CA
- Vivian Laquer, M.D. Dermatology · Irvine, CA
- Hal M. Weitzbuch, M.D., M.S., FAAD Dermatology · Calabasas, CA
- Gerard F. Acloque JR., M.D. Internal Medicine · Hollywood, FL
- Sandro Bacchelli, MD Family Medicine · Hollywood, FL
- Renato C. Dominguez, MD Internal Medicine · Miami, FL
- Brian J. Feinstein, D.O. Dermatology · Delray Beach, FL
- Stephen J. Lockwood, MD Dermatology · Brandon, FL
- Tory Sullivan, M.D. Dermatology · North Miami Beach, FL
- Scott A. Fretzin, M.D. Dermatology · Indianapolis, IN
- Cindy E. Owen, M.D. Dermatology · Louisville, KY
- Martina Porter, MD Dermatology · Boston, MA
- Steven D. Daveluy, MD Dermatology · Dearborn, MI
- Ali Moiin, MD Dermatology · Troy, MI
- Stephen M. Schleicher, M.D. Dermatology · Sugarloaf, PA
- Joe K. Tung, MD, MBA Dermatology · Pittsburgh, PA
- Katherine B. Reed, M.D. Dermatology · Spokane, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Encore Medical Research Llc $168,928
- Palm Harbor Dermatology PA PAlm Harbor Dermatology PA Dba True Clinical Research $117,870
- Wayne Health Obgyn $100,647
- Best Skin Research Llc $80,815
- University of Pittsburgh Medical Center Hillman Cancer Center $73,791
- Revival Research Institute Llc $71,248
- Encore Medical Research of Boynton Beach Llc $70,057
- Ds Research of Kentucky, Llc $68,770
- Dawes Fretzin Clinical Research Gro LLC $67,957
- Encore Medical Research of Weston Llc $50,476
- Moore Clnical Research Inc $37,355
- Clincove Inc $32,650
- Ziaderm Research Llc $25,246
- Dermatology Specialists of Spokane $20,736
- Paradigm Clinical Research Centers, Inc $19,766
- Moore Clinical Research $16,601
- First Oc Dermatology Research Inc $11,888
- Beth Israel Deaconess Medical Center, MA $11,070
- Clinical Trials Management Services, Llc $8,000
- Nova Research Institute Llc $7,600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.